- Home
- CYTK vs VRNS Comparison
CYTK vs VRNS Comparison
Compare CYTK & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTK
- VRNS
- Stock Information
- Founded
- CYTK 1997
- VRNS 2004
- Country
- CYTK United States
- VRNS United States
- Employees
- CYTK N/A
- VRNS N/A
- Industry
- CYTK Biotechnology: Pharmaceutical Preparations
- VRNS Computer Software: Prepackaged Software
- Sector
- CYTK Health Care
- VRNS Technology
- Exchange
- CYTK Nasdaq
- VRNS Nasdaq
- Market Cap
- CYTK 4.4B
- VRNS 4.4B
- IPO Year
- CYTK 2004
- VRNS 2014
- Fundamental
- Price
- CYTK $38.62
- VRNS $58.41
- Analyst Decision
- CYTK Buy
- VRNS Buy
- Analyst Count
- CYTK 13
- VRNS 16
- Target Price
- CYTK $71.58
- VRNS $59.56
- AVG Volume (30 Days)
- CYTK 1.4M
- VRNS 1.7M
- Earning Date
- CYTK 08-07-2025
- VRNS 07-29-2025
- Dividend Yield
- CYTK N/A
- VRNS N/A
- EPS Growth
- CYTK N/A
- VRNS N/A
- EPS
- CYTK N/A
- VRNS N/A
- Revenue
- CYTK $85,738,000.00
- VRNS $595,168,000.00
- Revenue This Year
- CYTK $27.08
- VRNS $14.92
- Revenue Next Year
- CYTK $652.09
- VRNS $16.53
- P/E Ratio
- CYTK N/A
- VRNS N/A
- Revenue Growth
- CYTK 2635.74
- VRNS 14.29
- 52 Week Low
- CYTK $29.31
- VRNS $36.53
- 52 Week High
- CYTK $59.39
- VRNS $60.58
- Technical
- Relative Strength Index (RSI)
- CYTK 60.89
- VRNS 62.24
- Support Level
- CYTK $32.89
- VRNS $53.93
- Resistance Level
- CYTK $36.79
- VRNS $58.26
- Average True Range (ATR)
- CYTK 1.73
- VRNS 2.01
- MACD
- CYTK 0.15
- VRNS 0.15
- Stochastic Oscillator
- CYTK 91.77
- VRNS 90.99
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.